Sign in
Not yet recruitingPhase 2

Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France15 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
72 people, planned
Started
May 2026
Expected to end
May 2030
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Fecal microbiota transplantation (FMT)
  • Sham-transplantation (placebo)
Record updated
17 March 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 44 criteriaShow less

Who can take part

  • Males or females
  • Age ≥18 and ≤75 years
  • Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
  • IBD diagnosed according to international guidelines (presence of endoscopic and histologic signs)
  • IBD inactive for at least 6 months (defined by no evidence of flare and no change in treatment)
  • ALP ≥ 1.3 ULN (at least 2 times within a 3 months pre-inclusion period) or elevated total bilirubin ≤50 umol/l (with concomitant elevated direct bilirubin)
  • Treatment with UDCA (13-23 mg/kg/d) for at least 6 months and at the same dosage for at least 3 months
  • Using contraceptive in women of childbearing potential and agrees to pursue it from inclusion until week 48. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly
  • Written informed consent signed
  • Subject affiliated to the French
  • Social Security System

Who cannot take part

  • History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis
  • Prior liver transplantation
  • Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
  • History of colorectal carcinoma or high-grade dypsplasia in previous screening colonoscopy
  • Current treatment with biologics (anti-TNF agent, vedolizumab, ustekinumab) or JAK inhibitors (tofacitinnib) or prednisone > 10 mg/day or budesonide > 3 mg /day) (or treatment initiated less than one month)
  • Participation in another interventional research without prior consultation with the investigator responsible for the patient's monitoring in the present study (participation in other non-interventional studies is permitted)
  • No treatment with antibiotics, antifungics or probiotics < 4 weeks
  • Hepatic comorbidity: HBV infection (defined by positive Ag HBS), HCV infection (defined by positive HCV RNA), alcohol abuse (defined by alcohol intake > 30g/day), metabolic dysfunction associated steatohepatitis, primary biliary cholangitis, Hemochromatosis, Wilson disease, α1-antitrypsin deficiency, celiac disease
  • HIV infection
  • History of or established or suspected hepatobiliary carcinoma
  • History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to inclusion)
  • Dosage changes of treatment for liver disease in the last 3 months or new treatment for liver disease started in the last 3 months
  • History of total colectomy
  • Current active IBD defined by a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn's Disease Activity Index (CDAI) > 150 in patients with Crohn's disease
  • Unable to consent, subject to legal or administrative decision (protection measure or deprivation of liberty) or involuntary psychiatric care
  • No other hepatic pathology: HBV (positive HBs Ag), HCV (positive HCV antibody and positive PCR), autoimmune hepatitis
  • No HIV infection (positive serology HIV1+2 antibodies)
  • No documented Clostridium difficile infection at inclusion or < 10 days preceding randomization (in case of infection discovered at inclusion)
  • Autoimmune hepatitis defined by the presence of moderate to severe interface hepatitis documented on liver biopsy and at least 1 of the 2 following criteria: AST or ALT > 5 ULN, Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
  • AST or ALT > 7 ULN in the last 3 months
  • Platelets count in the last 3 months < 100 000/mm3
  • Albumin in the last 3 months <35g/L
  • Renal insufficiency (clearance<60 ml/min)
  • Small duct PSC
  • Secondary sclerosing cholangitis (notably IgG4-associated cholangitis)
  • Cirrhosis defined by Liver elastometry >14.4 kPa or by current or past decompensation of cirrhosis
  • Prothrombin index in the last 3 months < 70%
  • Any severe comorbidity that may reduce life expectancy
  • Changes in IBD treatment or initiation of a new treatment for IBD in the last 3 months
  • Any contra-indication to swallow capsules
  • Pregnancy or desire for pregnancy or breastfeeding; Randomization criteria
  • No pregnancy (or desire for in the next year)
  • Available FMT with EBV and CMV compatibility

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT) on ALP and bilirubin compared to sham transplantation in addition to ursodeoxycholic acid (UDCA) treatment in PSC patients.

The 2 groups in the trial

  • Fecal microbiotaTreatment being tested

    FMT with stools from healthy donors 3 sessions of FMT in addition to standard UDCA therapy. First session of FMT: during a colonoscopy. Second and third session of FMT: 20 FMT capsules at week 12 and 24

    Treatment: Fecal microbiota transplantation (FMT)

  • Sham transplantationSham treatment, for comparison

    3 sessions of sham transplantation in addition to standard UDCA therapy. First session of sham transplantation: during a colonoscopy Second and third session of sham transplantation: 20 placebo capsules at week 12 and 24.

    Treatment: Sham-transplantation (placebo)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from NCT07477782, who can take part
Record updated
17 March 2026